Tumor Metabolism and Associated Serum Metabolites Define Prognostic Subtypes of Asian Hepatocellular Carcinoma

Overview

Journal Sci Rep

Specialty Science

Date 2021 Jun 9

PMID 34103600

Citations 4

Authors

Yotsawat Pomyen

Anuradha Budhu

Jittiporn Chaisaingmongkol

Marshonna Forgues

Hien Dang

Mathuros Ruchirawat

Chulabhorn Mahidol

Xin Wei Wang

Affiliations

Soon will be listed here.

Abstract

Treatment effectiveness in hepatocellular carcinoma (HCC) depends on early detection and precision-medicine-based patient stratification for targeted therapies. However, the lack of robust biomarkers, particularly a non-invasive diagnostic tool, precludes significant improvement of clinical outcomes for HCC patients. Serum metabolites are one of the best non-invasive means for determining patient prognosis, as they are stable end-products of biochemical processes in human body. In this study, we aimed to identify prognostic serum metabolites in HCC. To determine serum metabolites that were relevant and representative of the tissue status, we performed a two-step correlation analysis to first determine associations between metabolic genes and tissue metabolites, and second, between tissue metabolites and serum metabolites among 49 HCC patients, which were then validated in 408 additional Asian HCC patients with mixed etiologies. We found that certain metabolic genes, tissue metabolites and serum metabolites can independently stratify HCC patients into prognostic subgroups, which are consistent across these different data types and our previous findings. The metabolic subtypes are associated with β-oxidation process in fatty acid metabolism, where patients with worse survival outcome have dysregulated fatty acid metabolism. These serum metabolites may be used as non-invasive biomarkers to define prognostic tumor molecular subtypes for HCC.

Citing Articles

Metabolomic insights into pathogenesis and therapeutic potential in adult acute lymphoblastic leukemia.

Wang J, Gui T, Jiao B, Liu X, Ma X, Wang C Proc Natl Acad Sci U S A. 2025; 122(7):e2423169122.

PMID: 39946534 PMC: 11848409. DOI: 10.1073/pnas.2423169122.

Tumor energy metabolism: implications for therapeutic targets.

Hu Y, Liu W, Fang W, Dong Y, Zhang H, Luo Q Mol Biomed. 2024; 5(1):63.

PMID: 39609317 PMC: 11604893. DOI: 10.1186/s43556-024-00229-4.

Biomarkers for immunotherapy of hepatocellular carcinoma.

Greten T, Villanueva A, Korangy F, Ruf B, Yarchoan M, Ma L Nat Rev Clin Oncol. 2023; 20(11):780-798.

PMID: 37726418 DOI: 10.1038/s41571-023-00816-4.

Gut dysbiosis in Thai intrahepatic cholangiocarcinoma and hepatocellular carcinoma.

Pomyen Y, Chaisaingmongkol J, Rabibhadana S, Pupacdi B, Sripan D, Chornkrathok C Sci Rep. 2023; 13(1):11406.

PMID: 37452065 PMC: 10349051. DOI: 10.1038/s41598-023-38307-2.

The gut-liver axis: host microbiota interactions shape hepatocarcinogenesis.

Silveira M, Bilodeau S, Greten T, Wang X, Trinchieri G Trends Cancer. 2022; 8(7):583-597.

PMID: 35331674 PMC: 9232941. DOI: 10.1016/j.trecan.2022.02.009.

References

Woo H, Lee J, Yoon J, Kim C, Lee H, Jang J . Identification of a cholangiocarcinoma-like gene expression trait in hepatocellular carcinoma. Cancer Res. 2010; 70(8):3034-41. PMC: 3498758. DOI: 10.1158/0008-5472.CAN-09-2823. View

Clayton T, Baker D, Lindon J, Everett J, Nicholson J . Pharmacometabonomic identification of a significant host-microbiome metabolic interaction affecting human drug metabolism. Proc Natl Acad Sci U S A. 2009; 106(34):14728-33. PMC: 2731842. DOI: 10.1073/pnas.0904489106. View

Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin D, Pineros M . Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. 2018; 144(8):1941-1953. DOI: 10.1002/ijc.31937. View

Wang B, Chen D, Chen Y, Hu Z, Cao M, Xie Q . Metabonomic profiles discriminate hepatocellular carcinoma from liver cirrhosis by ultraperformance liquid chromatography-mass spectrometry. J Proteome Res. 2011; 11(2):1217-27. DOI: 10.1021/pr2009252. View

Kim E, Lisby A, Ma C, Lo N, Ehmer U, Hayer K . Promotion of growth factor signaling as a critical function of β-catenin during HCC progression. Nat Commun. 2019; 10(1):1909. PMC: 6478918. DOI: 10.1038/s41467-019-09780-z. View

Ogata N, Matsushima N, Shibata T . Pharmacokinetics of wood creosote: glucuronic acid and sulfate conjugation of phenolic compounds. Pharmacology. 1995; 51(3):195-204. DOI: 10.1159/000139335. View

Wu T, Wei C, Pan Y, Hsu R, Wu C, Yu Y . The uremic toxin p-cresyl sulfate induces proliferation and migration of clear cell renal cell carcinoma via microRNA-21/ HIF-1α axis signals. Sci Rep. 2019; 9(1):3207. PMC: 6397167. DOI: 10.1038/s41598-019-39646-9. View

Pornputtapong N, Nookaew I, Nielsen J . Human metabolic atlas: an online resource for human metabolism. Database (Oxford). 2015; 2015:bav068. PMC: 4513696. DOI: 10.1093/database/bav068. View

Shariff M, Kim J, G Ladep N, Crossey M, Koomson L, Zabron A . Urinary Metabotyping of Hepatocellular Carcinoma in a UK Cohort Using Proton Nuclear Magnetic Resonance Spectroscopy. J Clin Exp Hepatol. 2016; 6(3):186-194. PMC: 5052404. DOI: 10.1016/j.jceh.2016.03.003. View

10.

Llovet J, Montal R, Sia D, Finn R . Molecular therapies and precision medicine for hepatocellular carcinoma. Nat Rev Clin Oncol. 2018; 15(10):599-616. DOI: 10.1038/s41571-018-0073-4. View

11.

Lee J, Chu I, Heo J, Calvisi D, Sun Z, Roskams T . Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling. Hepatology. 2004; 40(3):667-76. DOI: 10.1002/hep.20375. View

12.

Vanholder R, Schepers E, Pletinck A, Nagler E, Glorieux G . The uremic toxicity of indoxyl sulfate and p-cresyl sulfate: a systematic review. J Am Soc Nephrol. 2014; 25(9):1897-907. PMC: 4147984. DOI: 10.1681/ASN.2013101062. View

13.

Mardinoglu A, Agren R, Kampf C, Asplund A, Uhlen M, Nielsen J . Genome-scale metabolic modelling of hepatocytes reveals serine deficiency in patients with non-alcoholic fatty liver disease. Nat Commun. 2014; 5:3083. DOI: 10.1038/ncomms4083. View

14.

Sun C, Young G, Hsieh Y, Chen Y, Wu M, Wu V . Protein-bound uremic toxins induce tissue remodeling by targeting the EGF receptor. J Am Soc Nephrol. 2014; 26(2):281-90. PMC: 4310659. DOI: 10.1681/ASN.2014010021. View

15.

Leroi C, Adam P, Khamduang W, Kawilapat S, Ngo-Giang-Huong N, Ongwandee S . Prevalence of chronic hepatitis B virus infection in Thailand: a systematic review and meta-analysis. Int J Infect Dis. 2016; 51:36-43. DOI: 10.1016/j.ijid.2016.08.017. View

16.

Marrero J, Kulik L, Sirlin C, Zhu A, Finn R, Abecassis M . Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology. 2018; 68(2):723-750. DOI: 10.1002/hep.29913. View

17.

Huang Q, Tan Y, Yin P, Ye G, Gao P, Lu X . Metabolic characterization of hepatocellular carcinoma using nontargeted tissue metabolomics. Cancer Res. 2013; 73(16):4992-5002. DOI: 10.1158/0008-5472.CAN-13-0308. View

18.

Anstee Q, Reeves H, Kotsiliti E, Govaere O, Heikenwalder M . From NASH to HCC: current concepts and future challenges. Nat Rev Gastroenterol Hepatol. 2019; 16(7):411-428. DOI: 10.1038/s41575-019-0145-7. View

19.

Gouas D, Shi H, Hainaut P . The aflatoxin-induced TP53 mutation at codon 249 (R249S): biomarker of exposure, early detection and target for therapy. Cancer Lett. 2009; 286(1):29-37. DOI: 10.1016/j.canlet.2009.02.057. View

20.

Chen S, Kong H, Lu X, Li Y, Yin P, Zeng Z . Pseudotargeted metabolomics method and its application in serum biomarker discovery for hepatocellular carcinoma based on ultra high-performance liquid chromatography/triple quadrupole mass spectrometry. Anal Chem. 2013; 85(17):8326-33. DOI: 10.1021/ac4016787. View